LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Pliant Therapeutics Inc

Uždarymo kaina

1.29 -3.01

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.28

Max

1.34

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.4M

-56M

Pelnas, tenkantis vienai akcijai

-0.92

Darbuotojai

171

EBITDA

-10M

-59M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+257.46% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-15M

83M

Ankstesnė atidarymo kaina

4.3

Ankstesnė uždarymo kaina

1.29

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Pliant Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-23 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

2025-05-23 21:57; UTC

Karštos akcijos

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

2025-05-23 21:15; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

2025-05-23 21:04; UTC

Įsigijimai, susijungimai, perėmimai

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

2025-05-23 20:56; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Salesforce Back in Deal Talks With Informatica -- WSJ

2025-05-23 20:51; UTC

Svarbiausios naujienos

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

2025-05-23 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-05-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-23 20:41; UTC

Svarbiausios naujienos

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

2025-05-23 20:28; UTC

Svarbiausios naujienos

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

2025-05-23 20:06; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

2025-05-23 20:06; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

2025-05-23 19:50; UTC

Svarbiausios naujienos

Trump's Tariffs: Where Things Stand -- 16th Update

2025-05-23 19:28; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

2025-05-23 19:28; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

2025-05-23 19:27; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

2025-05-23 19:20; UTC

Rinkos pokalbiai

Crude Futures Post Modest Weekly Losses -- Market Talk

2025-05-23 19:18; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

2025-05-23 18:57; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

2025-05-23 18:54; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

2025-05-23 18:53; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

2025-05-23 18:52; UTC

Įsigijimai, susijungimai, perėmimai

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

2025-05-23 18:13; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-05-23 18:13; UTC

Rinkos pokalbiai

Gold Trades Higher on Reminder of Risk -- Market Talk

2025-05-23 18:00; UTC

Svarbiausios naujienos

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

2025-05-23 17:51; UTC

Rinkos pokalbiai
Uždarbis

Workday Sees Higher Bar for Guidance -- Market Talk

2025-05-23 17:42; UTC

Svarbiausios naujienos

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

2025-05-23 17:39; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

2025-05-23 17:07; UTC

Svarbiausios naujienos

Trump's Tariffs: Where Things Stand -- 15th Update

2025-05-23 17:04; UTC

Rinkos pokalbiai
Uždarbis

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Akcijų palyginimas

Kainos pokytis

Pliant Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

257.46% į viršų

12 mėnesių prognozė

Vidutinis 4.79 USD  257.46%

Aukščiausias 17 USD

Žemiausias 1.5 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pliant Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

11 ratings

1

Pirkti

10

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.43 / 1.6Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.